Advancements and challenges in biomarker testing for tumors of the luminal gastrointestinal tract: current practice guidelines and emerging markers

Diagnostic Histopathology Pub Date : 2025-04-11 DOI:10.1016/j.mpdhp.2025.03.011

Ashley Lauren Hein, Erika Hissong

引用次数: 0

Abstract

Gastrointestinal tract tumors represent a major cause of morbidity and mortality world-wide. With recent technological advancements, the emergence of new biomarkers that offer diagnostic or prognostic information, monitor disease burden, and guide therapy has drastically enhanced our ability to provide effective and timely personalized medicine. Herein, we discuss the array of biomarkers which are currently recommended for clinical use in tumors of the luminal gastrointestinal tract and discuss several recently discovered biomarkers that have shown promising results.

查看原文本刊更多论文

胃肠道肿瘤生物标志物检测的进展和挑战：当前实践指南和新兴标志物

胃肠道肿瘤是世界范围内发病率和死亡率的主要原因。随着最近技术的进步，新的生物标志物的出现，提供诊断或预后信息，监测疾病负担，指导治疗，大大提高了我们提供有效和及时的个性化医疗的能力。在此，我们讨论了目前推荐用于临床应用的一系列生物标志物，并讨论了最近发现的几种显示出有希望结果的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diagnostic Histopathology Medicine-Pathology and Forensic Medicine

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： This monthly review journal aims to provide the practising diagnostic pathologist and trainee pathologist with up-to-date reviews on histopathology and cytology and related technical advances. Each issue contains invited articles on a variety of topics from experts in the field and includes a mini-symposium exploring one subject in greater depth. Articles consist of system-based, disease-based reviews and advances in technology. They update the readers on day-to-day diagnostic work and keep them informed of important new developments. An additional feature is the short section devoted to hypotheses; these have been refereed. There is also a correspondence section.